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Genetic and Biochemical Characterization of a Novel Metallo-
-Lactamase, TMB-1, from an Achromobacter xylosoxidans Strain
Isolated in Tripoli, Libya
Allaaeddin El Salabi,a Pardha Saradhi Borra,d Mark A. Toleman,a Ørjan Samuelsen,b and Timothy R. Walsha,c
Cardiff University, Cardiff, United Kingdoma; Reference Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University
Hospital of North Norway, Tromsø, Norwayb; University of Queensland, Centre for Clinical Research, Queensland, Australiac; and Research Group for Host-Microbe
Interactions, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, Tromsø, Norwayd
An Achromobacter xylosoxidans strain from the Tripoli central hospital produced a unique metallo--lactamase, designated
TMB-1, which is related to DIM-1 (62%) and GIM-1 (51%). blaTMB-1 was embedded in a class 1 integron and located on the chro-
mosome. The TMB-1-lactamase has lower kcat values than both DIM-1 and GIM-1 with cephalosporins and carbapenems. The
Km values were more similar to those of GIM-1 than those of DIM-1, with the overall kcat/Km values being lower than those for
GIM-1 and DIM-1.
Mobile metallo--lactamases (MBLs) are becoming increas-ingly frequent and pose significant challenges to the treat-
ment of Gram-negative infections worldwide, such that most
MBL-producing organisms are only susceptible to colistin (2).
These enzymes very efficiently hydrolyze all -lactams, including
carbapenems (with the exception of aztreonam), and the -lacta-
mase genes most often are located on transferable genetic plat-
forms, namely, either ISCR elements or class 1 integrons some-
times embedded in Tn21- or Tn402-like transposons (22, 24).
However, several recently characterized MBL genes have been
flanked or associated with ISCR elements, namely, blaSPM-1 with
ISCR4, blaNDM-1 with ISCR1, and blaAIM-1 with ISCR16 (6, 21).
Several differentMBL-type enzymes have been described, with
NDM, IMP, and VIM derivatives being the most widespread (2).
The blaIMP-like (17) and blaVIM-like (4) genes have been identified
in most clinically relevant bacteria belonging to the Enterobacteri-
aceae family, inPseudomonas spp., and inAcinetobacter spp., while
blaNDM-1 has mainly been found in Enterobacteriaceae (2, 6, 11,
27). Several otherMBLs have been identified in specific geograph-
ical locations, including SIM-1 from Acinetobacter baumannii in
Korea (8) and KHM-1 from Citrobacter freundii in Japan (16).
SPM-1 in Brazil (10, 23), GIM-1 in Germany (3), and AIM-1 in
Australia (T. R. Walsh, unpublished data) were all identified in
Pseudomonas aeruginosa.
As hospitalized patients are subject to infections by Gram-neg-
ative bacteria, and because in Libya adherence to internationally
accepted infection control policies is not optimal, we examined
the hospital wards and immediate hospital environment for resis-
tance to extended-spectrum cephalosporins. This study reports
these findings and further describes the genetic and biochemical
characterization of a novel MBL, TMB-1 (for Tripoli metallo--
lactamase), from Tripoli, Libya.
MATERIALS AND METHODS
Bacterial strains and susceptibility testing. A total of 38 nonclinical en-
vironmental swabs (from hospital wards, cafes, corridors, ventilators,
floors, bedside cabinets, oxygen cylinders, electrocardiograph machines,
and toilets of intensive care unit wards) were collected from and near four
major hospitals in Tripoli. The swabs were transferred to the laboratory in
transferring charcoal media, and bacteria were selected by culturing on
MacConkey agar (Oxoid, United Kingdom) supplemented with 100 mg/
liter vancomycin (to eliminate the growth of Gram-positive bacteria) and
2 mg/liter of ceftazidime to select for strains resistant to extended-spec-
trum cephalosporins. Isolates were initially identified by the use of Phoe-
nix (Becton andDickinson) and confirmed by API 20NE (bioMérieux, La
Plane, France). The susceptibility tests were performed by Phoenix 100
(Becton Dickinson, Oxford, United Kingdom) and Etest strips (bioMéri-
eux, La Plane, France) and were interpreted by the European Committee
on Antimicrobial Susceptibility Testing (http://www.eucast.org/eucast
_disk_diffusion_test/breakpoints/).
Phenotypic and molecular detection of MBLs. Phenotypic MBL de-
tectionwas carried out using the newMBLEtest stripswithmeropenemas
a substrate (bioMérieux, La Plane, France), and the results were inter-
preted according to the manufacturer’s instructions.
Identification of blaTMB-1, PCR experiments, and cloning.Molecu-
lar screening was performed on all isolates targeting the conserved region
of class 1 integrons, ISCR elements, and Tn21- and Tn402-like trans-
posons (Table 1). The PCR conditions were undertaken as previously
described (24). Where possible, PCR products from the conserved region
of class 1 integrons were run on 1% (wt/vol) agarose gels, purified, and
subcloned into Escherichia coliTOP10 cells (Invitrogen, Life Technologies
Ltd., Paisley, United Kingdom) and sequenced using the primers listed in
Table 1. All of the PCR products were run on 1% (wt/vol) agarose gel,
purified, and sequenced using an automated sequencer (AB 377; Perkin-
Elmer, CT).
Conjugation experiments. The conjugational transfer of antibiotic
resistance to the laboratory strain E. coli J53 (azide resistant) and Pseu-
domonas aeruginosa PAO1 (rifampin resistant) was carried out on blood
agar without selection. After 18 h, the mixed cultures were washed from
the plates, suspended in saline, and plated ontoMacConkey agar contain-
ing sodium azide (100 g/ml) and ceftazidime (2 g/ml) or rifampin (50
g/ml) and ceftazidime (2 g/ml). Ceftazidime-resistant colonies were
screened for blaTMB-1 by the primers listed in Table 1.
Hybridization. Gel plugs of chromosomal DNA were prepared and
restricted with S1 nuclease as previously described (27). Hybridization
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was performed in a gel. Briefly, the gel was dried for 5 h at 50°C and then
rehydrated in double-distilled water for 5 min before 30-min incubations
in a denaturing solution (0.5 M NaOH, 1.5 M NaCl) and neutralizing
solution (0.5M Tris-HCl, pH 7.5, 1.5MNaCl) at room temperature. The
gel was then prehybridized at 65°C using prehybridizing solution (20 ml;
6 SSC [1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate], 0.1%
[wt/vol] polyvinylpyrrolidone 400, 0.1% [wt/vol] Ficoll, 0.1% [wt/vol]
bovine serum albumin [BSA; Cohn fraction V], 0.5% [wt/vol] SDS, and
150 g/ml denatured calf thymus DNA) for at least 4 h before adding the
probe. The 32P-labeled probe was added for a minimum of 8 h at 65°C
before being removed with washes of 2 SSC, 0.1% SDS for 1 h, followed
by 0.1 SSC, 0.1% SDS for 3 h; both washes were performed at 65°C.
blaTMB-1 probes were labeled with
32P by using a random primer tech-
nique (Stratagene, La Jolla, CA).
Purification of TMB-1. To negate posttranslational modification in
an unnatural host, TMB-1 was purified directly from strain AES301,
which was grown overnight at 37°C in Terrific broth (Sigma, St. Louis,
MO). TMB-1 was purified from the periplasm (15), followed by ion ex-
change (Q-Sepharose HP column; Pharmacia, GE Healthcare, United
Kingdom) and gel filtration (Superdex 200 column; GEHealthcare) using
50 mM Tris (pH 7.2), 100 MZnCl2, 0.02% (wt/vol) sodium azide, with
or without NaCl, as the buffer system. Fractions containing TMB-1 were
FIG 1 Genetic context of two class 1 integrons found in A. xylosoxidans and the primers used to sequence the structures. (A) Class 1 integron consisting of the
gene cassettes containing dhfrA4, aacA4, blaOXA-4, and the qacE/sulL fusion. (B) Class 1 integron consisting of the gene cassettes containing blaTMB-1, aacA4,
blaOXA-4, and qacE/sulL. The white ellipses represent the hybrid promoter from intI1. The black ellipses represent the 59-bp elements at the start of each gene
cassette. The arrows depict primers used to amplify and sequence the integrons, and the sequences are given in Table 1.
TABLE 1 Primers used in this study
Gene target Primer no.a Primer name Primer sequence Reference or source
Integrase gene 1 VAF GCC TGT TCG GTT CGT AAG CT 22
Quaternary ammonium compound 2 QacR CGG ATG TTG CGA TTA CTT CG 22
TMB-1 3 Trip-1F61 GCC AAC GAA GAA ATA CCC GC This study
TMB-1 4 Trip2-10 TGG GCT AGG TTA CAC TGG TG This study
TMB-1 5 Trip617R TTC TAG CGG ATT GTG GCC AC This study
TMB-1 6 Trip2 CAA GGA GCT CAT TCA AAGG This study
TMB-1 7 Trip1 GGA GCA GGC AAG GAG CT This study
TMB-1 8 Trip75 ACC CGG ATT GGA AGT TGA GG This study
TMB-1 9 Trip1 FF TGA TCA GTG GCC ACA ATC CG This study
TMB-1 10 Trip1 F CGG ATT GTG GCC ACT GAT CA This study
dhfrA 11 dhfrA 1F CGA AGA ATG GAG TTA TCG GG This study
dhfrA 12 dhfrA 1R GTT AGA GGC GAA GTC TTG GG This study
dhfrA 13 dhfrA 1FF CCC AAG ACT TCG CCT CTA AC This study
aac6II 14 aac6II R GGC GTC GGC TTG AAT GAG TT This study
aac6II 15 aac6II F AAG TGG CAG CAA CGG ATT CG This study
aac6II 16 aac6II FR GAA TCC GTT GCT GCC ACT TG This study
aac6II 17 aac6II FF CAA CTC ATT CAA GCC GAC GC This study
Oxa-4 18 oxa-4-FR CAC TTA TGG CAT TTG ATG CG This study
Oxa-4 19 oxa-4-F CGC ATC AAA TGC CAT AAG TG This study
Tn21 NA Tn21 A GGG GTC GTC TCA GAA AAC GG 22
Tn21 NA Tn21 B GGA AAA TAA AGC ACG CTA AG 22
Tn402 NA Tn402F GTC GTT TTC AGA AGA CGG C 24
Tn402 NA Tn402R CTA TGC TCA ATA CTC GTG TGC 24
ISCR1 NA CRFF GGT TGC AAC GAC TCA AGCG 6
ISCR1 NA RECR1 CAC TCG TTT ACC GCT CAA GC 6
a The primer numbers are the same as those used in Fig. 1.
El Salabi et al.
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FIG 2 (A) Comparison of amino acid sequence of the -lactamase TMB-1 to those of other acquired MBLs (DIM-1, GIM-1, IMP-1, KMH-1, NDM-1, VIM-1,
SPM-1, and SIM-1) and several naturally occurring MBLs (IND-1 from Chryseobacterium indologenes, JOHN-1 from Flavobacterium johnsoniae, SLB-1 from
Shewanella livingstonensis, and SFB-1 from Shewanella frigidimarina). Shaded amino acids are those conserved with TMB-1. -Lactamase numbering was
according to the BBL nomenclature (5). (B) Secondary structure of TMB-1 compared to that of VIM-2. The -strands and -helixes are indicated above the
TMB-1 sequence. The conserved residues are indicated in black. The conservative amino acid substitutions are boxed. The figure was obtained using ESPript
software (http://espript.ibcp.fr/ESPript/ESPript/).
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analyzed using nitrocefin with or without EDTA, and the fractions were
analyzed by SDS-PAGE (Invitrogen, CA). TMB-1 was concentrated to
1.94 mg/ml using ultrafiltration (Millipore, MA).
Kinetics assays. Steady-state kinetics were performed at 25°C in a
spectrophotometer (SpectramaxPlus; Molecular Devices) using 96-well
plates (BD Falcon UV microplates; BD Biosciences) (15). All substrates
were tested as duplicates using 50 mM HEPES buffer, pH 7.2, 100 M
ZnCl2, 0.02% NaN3, and 0.1 mg/ml bovine serum albumin (Sigma-Al-
drich) as a buffer system. The kinetic data were analyzed by nonlinear
regression (GraphPad Software, San Diego, CA).
Nucleotide sequence accession number. The full sequence of the
3-kb class 1 integron reported in the present study has been submitted to
the EMBL/GenBank and assigned nucleotide sequence accession number
FR771847.
RESULTS AND DISCUSSION
Analysis of swabs fromTripoli hospitals.All swabsyielded isolates
capable of growing on 2g/ml ceftazidime and 10g/ml vancomy-
cin.All isolateswere screened for class 1 integrons andmobile genetic
elements (Tn21, Tn402, and ISCR elements), and 4 out of 38 isolates
were positive for class 1 integrons: one Achromobacter xylosoxidans
isolate (two integrons of3 kb), one Stenotrophomonas maltophilia
isolate (2.5 kb), and two isolates ofCitrobacter freundii, each positive
foraclass integronof1kb.Noneof the isolateswerepositive forTn21,
Tn402, and ISCR elements.A. xylosoxidansAES301displayed the fol-
lowing MIC profile: imipenem, 2 g/ml; meropenem, 4 g/ml;
cefepime, 16g/ml; ceftazidime, 8g/ml; cefotaxime, 32g/ml; az-
treonam, 16 g/ml; amikacin, 8 g/ml; gentamicin, 8 g/ml; cipro-
floxacin, 1 g/ml; and colistin, 0.5 g/ml. All isolates that grew on
media containingceftazidimewere screenedby theMBLEtest strip to
detect the presence of MBLs. Apart from the S. maltophilia isolate
(which naturally carries the L1MBL) (26), the only otherMBL-pos-
itive isolate was an A. xylosoxidans strain, designated AES301, pos-
sessing the class 1 integron, and it was investigated further.
Genetic analysis of carbapenemresistance inA. xylosoxidans
strain AES301. The sequencing analysis of the class 1 integron
PCR products from A. xylosoxidans AES301 revealed two nearly
identical integrons, the first possessing the gene cassette dhfrA4-
aacA4-blaOXA-4 and the second integron containing the gene cas-
sette blaTMB-1-aacA4-blaOXA-4 (Fig. 1). The carbapenem resistance
could not be mated to either E. coli DH5 or P. aeruginosa PAO1
recipients (data not shown), suggesting that the blaTMB-1 integron
is chromosomally located. This inference was supported by
Southern hybridization data using the blaTMB-1 gene as a probe,
which was back blotted to the A. xylosoxidans AES301 chromo-
some (data not shown) even though it produced several plasmids.
The TMB-1 gene contains 735 nucleotides and encodes a pro-
tein of 245 amino acids possessing all of the key motifs of Ambler
class B -lactamase. At the amino acid level, TMB-1 was most
closely related to DIM-1 (62%) and GIM-1 (51%) and showed
only 48, 31, and 29% identity to IMP-1, VIM-2, and NDM-1,
respectively (Fig. 2A). TMB-1 also possesses virtually the same key
residues as DIM-1 that make up the zinc binding residues and the
secondary residues supporting the active sites, including the pu-
tative loop used to facilitate the binding of -lactams during hy-
drolysis (Fig. 2A). A secondary structural comparison of TMB-1
to VIM-2 shows that TMB-1 possesses the key zinc binding resi-
dues for B1 MBLs, namely, His116, His118, and His196 (zinc 1)
and Asp120, Cys221, and His263 (zinc 2) (Fig. 2A). The most
noticeable difference between TMB-1 and VIM-2 is a gap in the N
terminus of the TMB-1 protein just before the beginning of the
first -sheet (1 in Fig. 2B). This gap in TMB-1 is situated just
prior to the flapping loop of VIM-2, which has been shown to
facilitate the binding and hydrolysis of substrates (1). Further,
there are several amino acid differences in this region, namely
(comparing VIM-2 to TMB-1), Q60S, S61R, F62V, D63E, A66G,
V67L, and a gap at position 65. This region is also diverse between
VIM-2 and VIM-7, where it has been suggested that it contributes
to a more flexible flapping loop (1). Interestingly, DIM-1 pos-
sesses the same sequence as TMB-1 in this region, with the excep-
tion of the gap and the amino acid changes N63E and F65W (12
anddata not shown). An additional gap inTMB-1 between7 and
8 compared to the VIM-2 sequence is also observed (Fig. 2B).
Kinetic properties of TMB-1.The kinetic properties of TMB-1
were compared to those of DIM-1 and GIM-1 (Table 2) and are
broadly similar, with the exception of the rate of turnover of sub-
strates (kcat values) (Table 2). TheKm values for TMB-1 are similar
to those of DIM-1 and GIM-1 for the penicillins and cephalospo-
rins but are larger for meropenem, indicating that TMB-1 binds
meropenem comparatively weakly. The kcat values for TMB-1 are
similar between the pencillins and GIM-1 but are markedly less
(30- to 260-fold) than those for both DIM-1 and GIM-1 for ce-
TABLE 2 Steady-state kinetic constants of TMB-1, DIM-1, and GIM-1
Compound
Steady-state kinetic constants of c:
TMB-1 DIM-1a GIM-1b
kcat (s
1) Km (M)
kcat/Km
(s1/M) kcat (s
1) Km (M)
kcat/Km
(s1/M) kcat (s
1) Km (M)
kcat/Km
(s1/M)
Ampicillin 3.3 27 0.122 20 110 0.182 3.3 20 0.165
Piperacillin 3.3 72 0.046 NR NR NR 6.9 69 0.1
Cefoxitin 0.3 69 0.004 8 20 0.4 8.3 206 0.04
Cefuroxime 0.1 9 0.011 NR NR NR 5.9 7 0.843
Ceftazidime 0.07 31 0.002 3 50 0.06 18 31 0.58
Ertapenem 0.4 31 0.013 NR NR NR NR NR NR
Imipenem 1.7 200 0.009 35 80 0.438 27 287 0.094
Meropenem 1.4 75 0.019 50 10 5 2.7 25 0.108
Aztreonam 0.01 ND ND 0.01 ND ND ND ND ND
a Data are from Poirel et al. (12).
b Data are from Castanheira et al. (3).
c NR, not reported. ND, not detected.
El Salabi et al.
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foxitin, cefuroxime, and ceftazidime (Table 2). TMB-1 also pos-
sesses lower kcat values for the carbapenems (2- to 36-fold) com-
pared to those of DIM-1 andGIM-1. These data further show that
the efficiency of the enzyme (kcat/Km) is lower for the cephalospo-
rins and carbapenems (Table 2). Such differences in kinetic values
are interesting, given that TMB-1 and DIM-1 are similar and that
their sequences in the VIM-2 flapping loop (15) are nearly iden-
tical, further suggesting that the reasons for these kinetic differ-
ences lie elsewhere in the TMB-1 structure (Fig. 2B).
Achromobacter is not themost important pathogen, although a
growing number of reports indicate that it is capable of causing
urinary tract infections (20), ocular infections (13), and the con-
tamination of dialysis (25) and ultrasound equipment (9), and it
can cause additional complications in cystic fibrosis patients (7,
14). Interestingly, although AES301 carrying TMB-1 was found in
a ward surface swab, the same strain could not be identified from
a clinical source; however, in Libya clinical diagnostic microbiol-
ogy laboratories may not scrutinize strains to the species level. To
date, only two cases of MBL genes (both blaVIM-2) have been re-
ported from Achromobacter spp., from Greece (19) and Korea
(18), and both were carried by class 1 integrons. This is the first
MBL reported from Libya, and being a new subclass, it provides
further evidence of the structural heterogeneity of this group of
-lactamases.
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